A double-blind, multi-center, multinational, randomized withdrawal study evaluating the efficacy and safety of SR58611A (350 mg q12) versus placebo in the prevention of depression relapse up to 1 year in patients with Major Depressive Disorder improved after 12 weeks of open treatment with SR58611A (350 mg q12).

Trial Profile

A double-blind, multi-center, multinational, randomized withdrawal study evaluating the efficacy and safety of SR58611A (350 mg q12) versus placebo in the prevention of depression relapse up to 1 year in patients with Major Depressive Disorder improved after 12 weeks of open treatment with SR58611A (350 mg q12).

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Amibegron (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms CALYPSO
  • Sponsors Sanofi
  • Most Recent Events

    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database)
    • 02 Dec 2008 Actual patient number (704) added as reported by ClinicalTrials.gov.
    • 02 Dec 2008 Status changed from active, no longer recruiting to completed to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top